September 26, 2024 Non Regulatory LIDDS has decided to concentrate its activities on three project areas
December 4, 2023 Non Regulatory Nomination Committee appointed for the Annual General Meeting 2024 in LIDDS
July 7, 2023 Non Regulatory Interview with LIDDS’s Chairman of the Board published on the company’s website
May 2, 2023 Non Regulatory LIDDS participates in LSX World Congress and ERLIG Therapeutic Oligo meetings
March 14, 2023 Non Regulatory LIDDS participates in BIO-Europe Spring and EACR Immuno-Oncology Meetings
January 23, 2023 Non Regulatory The subscription period in LIDDS’ rights issue is starting today and the CEO has participated in an interview with Erik Penser Bank
January 9, 2023 Non Regulatory LIDDS signs a deal with Alira Health on sell-side support in Licensing
December 8, 2022 Non Regulatory LIDDS presents at high-profile event in connection with Nobel Prize festivities
November 30, 2022 Non Regulatory Nomination Committee appointed for the Annual General Meeting 2023 in LIDDS
November 4, 2022 Non Regulatory Interview with LIDDS’ CEO Anders Månsson published on the company’s website
July 8, 2022 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in Israel
June 7, 2022 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in Japan and South Korea
February 17, 2022 Non Regulatory Invitation to LIDDS Capital Markets Day and presentation of new strategy and vision
December 29, 2021 Non Regulatory LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
December 20, 2021 Non Regulatory LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
December 17, 2021 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in China
November 17, 2021 Non Regulatory Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
September 28, 2021 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in Russia and Australia
May 28, 2021 Non Regulatory LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna
April 16, 2021 Non Regulatory Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®
April 8, 2021 Non Regulatory International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules
February 24, 2021 Non Regulatory LIDDS files patent application for method to treat brain cancer with intratumoral depot injections
February 4, 2021 Non Regulatory European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
December 22, 2020 Non Regulatory LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021
December 18, 2020 Non Regulatory Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot
November 18, 2020 Non Regulatory A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development
October 19, 2020 Non Regulatory LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020
January 14, 2020 Non Regulatory LIDDS: The United States Patent and Trademark Office has registered the LIDDS trademark NANOZOLID in the US
January 13, 2020 Non Regulatory LIDDS: Stockpicker´s buy recommendation for 2020 picks LIDDS share as one of twelve attractive Swedish companies
December 10, 2019 Non Regulatory LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from Redeye
December 2, 2019 Non Regulatory LIDDS Interview with the LPC-004 study investigator, Professor Laurence Klotz, about the LIDDS Liproca® Depot Phase IIb study results
September 24, 2019 Non Regulatory LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
August 28, 2019 Non Regulatory LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019
March 13, 2019 Non Regulatory LIDDS: First patient receives intratumoral NanoZolid®-docetaxel in Phase I study
March 6, 2019 Non Regulatory LIDDS: Final patient enrolled in Phase IIb Liproca® Depot prostate cancer study
February 5, 2019 Non Regulatory LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial
February 4, 2019 Non Regulatory LIDDS research activities in intratumoral immunotherapy are in line with leading oncology expert recommendations
November 16, 2018 Non Regulatory LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability
November 1, 2018 Non Regulatory LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability
June 25, 2018 Non Regulatory LIDDS’ NanoZolid® technology recognized through publication of scientific article in Journal of Drug Delivery Science and Technolog